Global Exocrine Pancreatic Insufficiency Market Size, Share - Growth Analysis Report and Forecast Trends 2026-2030

Exocrine Pancreatic Insufficiency refers to the deficient production or secretion of pancreatic digestive enzymes, leading to malabsorption, steatorrhea, weight loss, and nutritional deficiencies. The global market for EPI therapies and supportive care is estimated at $2.23 billion in 2025 and is projected to grow at approximately 4.74% annually over the coming years. Treatment is dominated by Pancreatic Enzyme Replacement Therapy, with pancrelipase-based products such as Creon forming the clinical standard of care for several decades.

• •Global market size estimated at $2.23 billion in 2025 with a 4.74% CAGR.
• •PERT, particularly pancrelipase formulations, remains the cornerstone of disease management.
• •Underdiagnosis remains a structural feature of the market, suggesting latent demand above reported prevalence.

The principal growth drivers include the rising prevalence of EPI secondary to chronic pancreatitis, cystic fibrosis, pancreatic cancer, and diabetes-related pancreatic dysfunction. Machine learning and retrospective epidemiological studies have demonstrated that EPI is significantly underdiagnosed, meaning improvements in case-finding and diagnostic protocols directly expand the treated patient population. Additionally, the long-term survival benefits associated with enzyme therapy in oncology cohorts, combined with growing health-economic evidence supporting PERT cost-effectiveness, are reinforcing payer and clinician adoption.

• •Improved identification of undiagnosed EPI cases through advanced analytics is expanding the addressable population.
• •Rising incidence of pancreatic cancer, diabetes, and chronic pancreatitis is increasing secondary EPI prevalence.
• •Health-economic data supporting the cost-effectiveness of enzyme therapy is strengthening reimbursement uptake.

The market is segmented by therapy type (PERT, nutritional support, and adjunctive treatments), by indication (chronic pancreatitis, cystic fibrosis, post-surgical, oncology-related, and diabetes-associated EPI), and by patient population (adult and pediatric). North America represents the largest regional market, supported by established reimbursement frameworks and high prescribing rates of branded pancrelipase products, while Europe follows closely with strong cystic fibrosis prevalence and standardized treatment guidelines. Emerging markets in Asia-Pacific are expected to contribute incremental growth as awareness and diagnostic infrastructure improve.

• •North America leads on the strength of mature reimbursement and high PERT prescribing rates.
• •Europe is supported by significant cystic fibrosis prevalence and guideline-driven treatment adoption.
• •Asia-Pacific represents the fastest-growing region as diagnostic capabilities and awareness expand.

What are the recent trends and outlook?

Key trends shaping the outlook include the integration of machine-learning tools into primary care to identify undiagnosed EPI patients, particularly within diabetes and post-pancreatic-surgery cohorts. Parallel advances in pancreatic bioartificial technologies and beta-cell research are broadening the long-term therapeutic landscape, even though PERT remains the immediate commercial focus through 2030. The market is expected to continue compounding at roughly 4.74% annually, supported by earlier diagnosis, expanded indication coverage, and incremental formulation improvements.

• •AI-driven case-finding is expected to materially reduce the EPI underdiagnosis gap over the forecast period.
• •Bioartificial pancreas and beta-cell technologies represent longer-term adjacencies but are not expected to displace PERT by 2030.
• •Steady mid-single-digit growth is anticipated through the late 2020s as awareness and treatment penetration deepen.